
Green-lipped mussel for knee osteoarthritis: a 2026 trial adds a signal, not certainty
A 2026 randomized trial of green-lipped mussel powder reported some improvements, but analysis choices and prior mixed evidence matter.
The 2026 trial is encouraging for some pain and function measures, but the primary result differed by analysis and does not settle product-wide effectiveness.
What was published in 2026
A randomized, double-blind, placebo-controlled trial published in 2026 tested green-lipped mussel powder in 100 adults aged 40 to 75 with mild-to-moderate knee osteoarthritis. Participants received 1,000 milligrams daily or placebo for 12 weeks. The prespecified primary endpoint was change in the total WOMAC score, which combines pain, stiffness and physical function.
The study is timely because green-lipped mussel products have been sold for years while earlier trials varied in formulation and quality. A new controlled trial can improve the evidence base, but it should be read alongside rather than in place of that history. One study rarely resolves a supplement question when commercial extracts differ.

The analysis population changed the headline
In the per-protocol analysis of 93 participants who completed the study, the total WOMAC score improved more with mussel powder than placebo. In the intention-to-treat analysis including all 100 randomized participants, the total score showed a favorable trend but did not reach conventional statistical significance. Physical function and visual-analog pain remained significantly better in that broader analysis.
Intention-to-treat analysis preserves the original randomization and is usually central to judging effectiveness. Per-protocol analysis can show what happened among adherent completers but may reintroduce differences between groups. The split result does not erase the signal; it makes the certainty and wording of the conclusion more important.
Pain improved while inflammatory markers did not
The trial reported favorable changes in pain-related outcomes, yet C-reactive protein and erythrocyte sedimentation rate did not differ significantly between groups. That is not necessarily contradictory. Symptoms, function and blood markers answer different questions, and a supplement should not be described as systemically anti-inflammatory merely because pain scores improved.
The absolute difference and the confidence interval should also be considered, not only the p value. A statistically detectable average does not guarantee a noticeable benefit for every participant. Individual responses vary, and short-term symptom change does not prove cartilage protection or slowed progression.

Earlier research remains mixed and formulation-specific
A 2021 systematic review pooled several green-lipped mussel trials and reported a moderate average pain effect, while stressing the limited number and quality of studies and uncertainty about the optimal format. Another six-month randomized trial published in 2024 examined a branded whole-powder product and found that product and outcome details affected interpretation.
Powders, lipid extracts and combined products should not be assumed equivalent. Marine-source allergies are a practical concern, and product quality includes identity, contaminants and stability. A trial of one standardized powder does not validate a different extract simply because both come from Perna canaliculus.
How this update should change a decision
The new study strengthens the case for further independent trials using transparent intention-to-treat analyses, longer follow-up and clearly characterized products. It does not establish green-lipped mussel as a disease-modifying treatment or a replacement for established osteoarthritis care. The 12-week time frame is especially important when marketing suggests long-term joint protection.
A consumer considering the tested type of product should discuss shellfish allergy, medicines, other supplements and the treatment goal with a clinician. A reasonable stop rule can prevent indefinite spending when no meaningful improvement occurs. The fairest 2026 headline is encouraging but qualified: some symptom measures improved, while the primary result depended on how the randomized group was analyzed.
The publication date also matters when comparing summaries. Reviews completed before this trial cannot include it, while promotional pages may cite the new result without the older mixed literature. A current assessment should hold both at once: the 2026 study adds information, and the broader evidence still contains variation and uncertainty. Future reviews will need to evaluate the new trial’s risk of bias, formulation and analysis alongside the rest rather than simply increasing the favorable-study count. Registration and protocol comparisons can help determine whether every reported outcome was planned. New evidence should be read carefully, not automatically celebrated.
Sources & further reading
- Efficacy and safety of green-lipped mussel powder in adults with knee osteoarthritis: randomized trial ↗
- The Effects of GreenShell Mussel Powder on physical performance and symptoms in knee osteoarthritis: randomized trial ↗
- Green-lipped mussel extract supplementation in osteoarthritis: a systematic review ↗
This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.